05 February 2013
Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation
Jun-Neng RoanABCDEF, Chen-Hsi ChouABCDE, Chih-Hsin HsuBCD, Shuan-Yin WuBCF, Yu-Ching HuangB, Yu-Jen YangD, Chwan-Yau LuoABCEFGDOI: 10.12659/AOT.883812
Ann Transplant 2013; 18:43-52
Abstract
BACKGROUND: The early phase of MPA exposure has rarely been investigated after solid organ transplantation, especially in heart transplantation patients. We evaluated the association between exposure to mycophenolic acid (MPA), a main metabolite of mycophenolate mofetil (MMF), and clinical events within 3 months after heart transplantation.
MATERIAL AND METHODS: Trough (C0) and area under the curve (AUC)0–12h levels of MPA and its metabolite, mycophenolic acid glucuronide (MPAG), were determined using high-performance liquid chromatography. Corresponding clinical endpoints included acute rejection or MMF-related adverse events (gastrointestinal symptoms, leucopenia, and anemia). AUC measurements (n=77) were collected from 21 patients. Dose-normalized C0 and AUC0–12h levels were used to evaluate the association between MPA or MPAG exposure and MMF-related adverse events.
RESULTS: No acute rejection or mortality occurred during the follow-up period. Twelve patients (57%) developed 13 MMF-related adverse events. The MMF dose was tapered from 2.50 g/day on D1 to 1.55±0.54 g/day on D90. Significantly higher levels of dose-normalized MPA C0 and AUC0–12h were associated with the events than with the absence of the events (C0: 1.04±0.42 vs. 0.84±0.85 µg/mL/g [p=0.047]; AUC0–12h: 20.37±3.21 vs. 14.97±1.13 µg × h/mL/g; [p=0.038]).
CONCLUSIONS: Dose-normalized MPA exposure may protect against MMF toxicity in the early stage after heart transplantation. The MMF dose can be decreased to near 1.5 g/day 3 months post-transplantation without jeopardizing patient safety; a well-planned, tapered MMF regimen should also be considered.
Keywords: mycophenolic acid exposure, Area Under Curve, Adverse events, Heart Transplantation
In Press
Original article
Steroid Use in ABO-Incompatible Kidney Transplants: Withdrawal vs MaintenanceAnn Transplant In Press; DOI: 10.12659/AOT.947747
Original article
Intra-Arterial Contrast-Enhanced Ultrasound for Transcatheter Thrombolysis in Post-Transplant Hepatic Arter...Ann Transplant In Press; DOI: 10.12659/AOT.947500
Original article
Early Atropine Protocol Enhances Dobutamine Stress Echocardiography in End-Stage Liver Disease: A Practical...Ann Transplant In Press; DOI: 10.12659/AOT.950166
Most Viewed Current Articles
15 Aug 2023 : Review article 7,358
Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ TransplantationDOI :10.12659/AOT.939750
Ann Transplant 2023; 28:e939750
03 Jan 2023 : Original article 7,222
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...DOI :10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
16 May 2023 : Original article 7,051
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...DOI :10.12659/AOT.939258
Ann Transplant 2023; 28:e939258
28 May 2024 : Original article 6,655
Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...DOI :10.12659/AOT.943281
Ann Transplant 2024; 29:e943281